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Dum Spiro Spero: 
While I Breathe I Hope









Define  Cystic Fibrosis (CF), how it 
manifests and its incidence
 List the different classes of genetic 
mutations
Discuss diagnosis and testing 
 Describe the therapeutic management 
of CF




1. Cystic fibrosis is part of the 





1. Cystic Fibrosis a disease that 
affects: Sweat glands, GI tract, 





1. In CF patients Azithromycin is only 





What is Cystic Fibrosis?
Cystic fibrosis is a 
progressive, genetic disease 
that causes persistent lung 
infections and limits the 
ability to breathe over time





Detected by newborn 
screening:58.4%




8Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
Question 1
1. Cystic fibrosis is part of the 





















Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
Question 2
1. Cystic Fibrosis a disease that 
affects: Sweat glands, GI tract, 













Science of CF: CFTR: Function. Johns Hopkins Cystic Fibrosis Center
http://www.cftr.info/about-cf/pathophysiology-of-cf/sweat-gland/how-cf-modifies-sweat-chloride-levels-at-the-cellular-level/ 
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Pancreas and GI Tract
 Pancreatic ducts are blocked by thick 
mucus
No release of pancreatic enzymes
Science of CF: CFTR: Function. Johns Hopkins Cystic Fibrosis Center 13
Airways




















15Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
Genetics
- Autosomal recessive 
genetic disorder
- 25% probability for 
the offspring
16Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018https://www.kalydeco.com/condition-overview
Cystic fibrosis mutation 
classification
17




 Pancreatic enzyme replacement 
therapy: 85.7%
 Supplemental feeding tube: 10.9%
 Supplemental feeding tube oral: 44.9%
Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
Diagnosis
Diagnosis prior to onset of symptoms
Cystic Fibrosis is part of the Newborn 
screening test
Newborn screen test/prenatal genetic 
test
 Immunoreactive trypsinogen test (IRT)
 Sweat test between 10 days to 4 weeks 
from birth
19
Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
https://www.healthline.com/health/cystic-fibrosis-carrier
https://www.cff.org/What-is-CF/Testing/Sweat-Test/
The gold standard test
 Sweat Test
 Measures the amount of chloride 
in the sweat
 Electrodes attached 
 Electrode 1 contains pilocarpine 
gel 
• A weak electrical current pushes the 
medication through skin ~5minutes
 Remove electrodes, clean and 
dry skin
 Collect sweat for 30 minutes
20
Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
Sweat Test. What is CF. Cystic Fibrosis Foundation
https://kidshealth.org/en/parents/sweat-test.html















Cystic Fibrosis related 
Metabolic Syndrome 
(CRMS)




(CFTR) gene mutation and 
related conditions






Pancreas and GI tract
 Fecal pancreatic elastase-1 (FE-1)
 Pancreatic insufficiency test
 2 weeks of age if no liquid stools
 Pancreatic enzyme replacement 
therapies (PERT)
 Patients with 2 mutation in the group I-III 
 Fecal elastase value < 200 
micrograms/stool
 Signs of malabsorption
Schwarzenberg SJ. et al.; Pancreatic enzymes Clinical Care Guidelines. Cystic Fibrosis foundation.2018 




 Infants: 450-900 lipase U/g or 2000-
4000 U/120ml of formula
Older children and adults: 500-4000 
lipase U/g of fat ingested or 500-2500  
U/kg/meal, 250-1250 U/kg/snack
Doses > 2500 lipase U/kg/meal or 
4000 U/g of fat  Investigate
 Doses >6000 lipase U/kg/meal 
associated with fibrosing colonopathy
23Schwarzenberg SJ. et al.; Pancreatic enzymes Clinical Care Guidelines. Cystic Fibrosis foundation.2018 
Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis March 2018
PERT Pearls
Only dispense prescribed product 
brand
 Enteric coated microencapsulated 
enzymes are most effective
 Excessive doses of PERT may result 
in abdominal pain/constipation
 Fat soluble vitamins measured once 
a year
24Schwarzenberg SJ. et al.; Pancreatic enzymes Clinical Care Guidelines. Cystic Fibrosis foundation.2018 
Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis March 2018
Therapy
Pancreas and GI tract
 Acid blockers to treat acid reflux 
(GERD), decrease acidity of 
environment or increase 
effectiveness of PERT
 Proton Pump Inhibitors 48.5% of CF 
patients
 H2 blockers 17.5% 
25Schwarzenberg SJ. et al.; Pancreatic enzymes Clinical Care Guidelines. Cystic Fibrosis foundation.2018 
Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis March 2018
Therapy
Lungs
• 2-4 times a day to open airwaysBronchodilators
• 2-4 times a day as osmotic agentHypertonic saline (HyperSal, PulmoSal)
• 2.5mg daily as mucolyticDornase alfa (Pulmozyme)
• To mobilize mucusChest Physiotherapy
• To prevent/treat lung infectionsAntibiotics
26
Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis March 2018
Therapy
Respiratory
 Short acting beta adrenergic receptor 
agonists 
 Immediately prior to nebulized 
hypertonic saline





27Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis. 2018
Reusable Nebulizer Pearls
Use bronchodilators 15-30 min before 
airway clearance treatments
Common side effects are tremor, 
nausea, rapid heart rate, nervousness
Clean and disinfect after each use
28Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis. 2018
Inhaled Hypertonic 
Saline 7%
 6 years and older
Moderate to severe 
lung disease






3- Increase mucociliary 
function
Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis March 2018
Simon RH, et al.; Cystic Fibrosis: Overview of the treatment of lung disease. Up-to-date
Dornase alfa (Pulmozyme)
 6 years and older
Mucolytic which decreases viscosity
 Reduces the decline in lung 
functioning and pulmonary 
exacerbations
 Side effects: Hoarseness, sore 
throat, and change in voice
30
Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis March 2018
Simon RH, et al.; Cystic Fibrosis: Overview of the treatment of lung disease. Up-to-date
Yang C et al.; Dornase alfa for cystic fibrosis. Cochrane Database Sys Rev. 2016
Incidence of respiratory 
pathogens
31
Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
MRSA Treatment
 Pulmonary exacerbations
 Vancomycin IV 
• 45-60mg/kg/day divided Q6-8
• 15-20mg/kg Q8-12hr adults
 Linezolid
• 10mg/kg IV/PO Q8hr for <12 years old
• 600mg IV/PO Q12hr for >11 years old
• Serotonin syndrome-drug interactions
• Peripheral/optic neuropathies
• Myelosuppression
32Aksamit TR.; et al.; Antibiotic management of Lung Infection in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus 
aureus, Gram Negative Bacteria, and Multiple Infections
MRSA treatment 
Outpatient setting
 Two oral agents are recommended
• Rifampin plus another oral agent
 High mucosal concentration
 Activity against biofilms
 Do not give monotherapy
 Worsening of GERD
 Decrease oral contraceptive effectiveness
• Add nebulized vancomycin to regime
 Effective and well tolerated. 
 Ongoing studies investigating the use of inhaled 
vancomycin
33Aksamit TR.; et al.; Antibiotic management of Lung Infection in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus 




Choose 1 from this column
Tobramycin 2.5-3.3mg/kg IV/IM Q6-8 
pediatric
5-7mg/kg IV Q24h adult
Ototoxicity, 
nephrotoxicity
Amikacin 10mg/kg/dose Q8hrs pediatric 
(traditional)
30mg/kg/dose Q24 pediatric 
(extended interval)




Colistin 3-5 ,g CBA/kg/day Q8hrs 
>5years old




Simon RH, et al.; Cystic Fibrosis: Overview of the treatment of lung disease. Up-to-date
35
Column B
Add one to column A
Ceftazidime 150-200mg/kg/day IV Q6h 
pediatric
90-150mg/kg/day IV Q8h adults
GI, rash
Meropenem 40mg/kg IV Q8h pediatric




Ciprofloxacin 10mg/kg IVQ8hrs-or-20mg/kg PO 
Q12h pediatric







Simon RH, et al.; Cystic Fibrosis: Overview of the treatment of lung disease. Up-to-date
Antipseudomonal Treatment
Inhaled Antibiotics
 Aztreonam (Cayston®) Inhalation solution
 Tobramycin (TOBI® Bethkis®, Kitabis 
Pak®) Inhalation solution
 Tobramycin (TOBI®, PodhalerTM)
Inhalation powder
36





Combination of 2 antipseudomonal 
agents
 Eradication of pseudomonas infection 
treatment recommendation
 28 days of inhaled tobramycin
 Followed by nebulized colistimethate plus 
oral ciprofloxacin for 3 months
 If failed eradication treatment, patient 
is diagnosed with chronic infection 
37Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis March 2018Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis March 2018
Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
Antipseudomonal treatment
Chronic infection
 Inhaled Tobramycin 300mg BID on 
alternative months
 6 years and older
 Extended indefinitely
 Tobramycin IV or IM: 10mg/kg/day 
divided 4 times a day
 Aztreonam 75mg on alternative 
months
 Showed superiority to Tobramycin for 
lung functioning 38
Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis March 2018
Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
Inhaled Antibiotic Pearls
 Solutions are administered via 
nebulizer
 Refer patients to CF care teams for 
instructions about specific nebulizer 
usage/cleaning
 Powders: four capsules twice/day
 Place one cap at a time in the inhalation 
device
 Breath slowly and deeply
 Hold brea h for 5 seconds 39
Azithromycin
 6 years and older
 Antimicrobial and anti-inflammatory 
properties
Chronic Pseudomonas aeruginosa 
infection-biofilms
 Not antipseudomonal agent
 Improve lung function 
 Linked to resistance when chronic 
use
40Castellani C. et al.; ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis March 2018Marshall B. et al.; 2017 Patient Registry. Annual Data Report. Cystic Fibrosis Foundation. 2018
Question 3
1. In CF patients Azithromycin is only 







 Ivacaftor (Kalydeco): 
 12 months to <6 years, and 7-14kg: 
50mg granules PO Q12h
 12 months to <6 years and >14kg: 75mg 
granules PO Q12h
 6 years and older: 150mg PO Q12h
42
Kalydeco (Ivacaftor) Medscape. 2018
Kalydeco (Ivacaftor) Tablet Label. FDA package insert. 2012
Kalydeco (Ivacaftor) to Treat Cystic Fibrosis. Cystic Fibrosis News Today. 2018
CFTR Modulator Therapies
Ivacaftor (Kalydeco)
 1 year and older
•ARRIVAL Trial
 For most CFTR mutations
•Not approved for two copies of the 
F508del mutation
 Side effects: headaches, upper 
respiratory tract infections, stomach 
pain, and diarrhea
43
Kalydeco (Ivacaftor) Medscape. 2018
Kalydeco (Ivacaftor) Tablet Label. FDA package insert. 2012
Kalydeco (Ivacaftor) to Treat Cystic Fibrosis. Cystic Fibrosis News Today. 2018
Orkambi (Ivacaftor/Lumacaftor) Medscape. 2018




 2-5 years old
• Weight <14kg: 100mg/125mg Oral granules 
PO Q12h
• Weight >14kg: 150mg/188mg Oral granuel
PO Q12h
 6-11 years old
• 2 tablets PO Q12h (100mg/125mg per tab)
 >12 years old
• 2 tablets PO Q12h (200mg/125mg)




 >12 years old
• 100/150mg (tezacaftor/ivacaftor) QAM 
followed by 150mg Ivacaftor 12 hours later
 For 26 specific types of mutations
Approved for 508del homozygous
45Symdeko (tezacaftor/ivacaftor) Tablet Label. FDA package insert. 2018
CFTR Modulator Therapies 
Pearls
 Taken with fatty meals i.e. eggs, 
peanut butter, cheese, etc. 
Mix granules with 5mL of yogurt, 
milk
CYP3A metabolized
46CFTR Modulator Therapies. Cystic Fibrosis Foundation
Immunizations 
 Influenza: 
 >6 months: Inactivated vaccine
 PCV13: 
 Up to 24 months old
 >65 years old
 PPSV23:
 After 2 years of age
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